Please ensure Javascript is enabled for purposes of website accessibility

Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot

By Brian Orelli, PhD - Mar 15, 2016 at 5:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors can't figure out how to value the biotech ahead of the FDA approval of cabozantinib.


What: As it's done so many times recently, Exelixis (EXEL 4.17%) ended down 10.4% on Tuesday on seemingly no news.

So what: It's the curse of the biotechs that have a majority of their value tied up in their pipelines. One day investors might love them, the next they might hate them.

Don't like the current situation? Just wait a few days.

In fact, Exelixis traded at the level it closed on Tuesday a few weeks ago. And last week, the stock closed higher and lower than Monday's close. The stock chart looks like an EKG reading.

EXEL Chart


Now what: Long-term investors needn't worry about the short-term changes in valuations. Sure it hurts on double-digit down says -- and is great on double-digit up days -- but the moves shouldn't have much effect on Exelixis' long-term value.

Years from now, we'll be talking about the sales of cabozantinib for kidney cancer -- and perhaps liver cancer as well -- rather than the daily gyrations of the stock price.

The schizophrenic stock chart could be because investors are worried about whether cabozantinib will be approved by U.S. and EU regulators, but it seems more likely they're confident in an approval but worried about the potential sales given Bristol-Myers Squibb's (BMY 1.64%) quick approval of Opdivo for kidney cancer. That Exelixis hasn't released the overall survival data, which would help investors compare the efficacy of the two, makes it hard for investors to know whether Exelixis or Bristol-Myers Squibb will be able to win the battle for kidney cancer patients.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
$22.22 (4.17%) $0.89
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$78.96 (1.64%) $1.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.